aid: complementtherapeutics name: Complementtherapeutics image: https://irp.cdn-website.com/031fc6f5/dms3rep/multi/opt/close-up-view-of-mature-human-eye-with-data-illust-2026-01-06-00-42-35-utc-1920w.jpg description: 'Complement Therapeutics is a clinical-stage biotechnology company focused on developing precision therapies for complement-mediated diseases, including geographic atrophy, a form of age-related macular degeneration. The company advances novel treatments targeting the complement system, with a pipeline of programs and a dedicated scientific team.' url: https://raw.githubusercontent.com/api-evangelist/complementtherapeutics/refs/heads/main/apis.yml x-type: company x-source: harvest:secondary-market x-tier: profiled x-tier-reason: enrichment pass 2026-10-10 (modular-v1; was harvest) specificationVersion: '0.20' created: '2026-10-09' modified: '2026-10-09' tags: - Biotechnology - Clinical-stage - Complement System - Therapeutics - Company maintainers: - FN: Kin Lane email: kin@apievangelist.com - FN: APIs.json email: info@apis.io common: - type: LLMsTxt url: llms/complementtherapeutics-llms.txt - type: Hosts url: hosts/complementtherapeutics-hosts.yml - type: PrivacyPolicy url: https://www.complementtx.com/privacy - type: Blog url: https://www.complementtx.com/blog - type: DomainSecurity url: security/complementtherapeutics-domain-security.yml - type: Website url: https://www.complementtx.com apis: [] x-coverage: state: none reason: no-developer-program method: derived generated: '2026-10-10' generator: derive-coverage.py (pre-flight evidence) detail: >- the company publishes no developer documentation host and no machine-readable contract on its own domain evidence: - url: https://www.complementtx.com/mcp status: 403 - url: https://www.complementtx.com status: 200 - url: https://equityzen.com/company/complementtherapeutics status: 403 x-enrichment: date: '2026-10-10' status: enriched artifacts_added: 10 pass: modular-v1 engine: identity=local,contract=local,surfaces=local,docs=local,regulatory=local